Unicycive Therapeutics Inc (UNCY) Stock Analysis
Verdict: HOLD
A binary bet on Renazorb approval: high-conviction analyst targets of $22 clash with a 12-month cash runway and peers trading at lower P/B.
Investment score: 62/100
Analysis as of
Is Unicycive Therapeutics Inc stock worth reviewing? AI model thesis
Speculative buy based on strong technical recovery and extreme analyst upside ($22 target), despite pre-revenue status and high cash burn.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Unicycive Therapeutics Inc opportunities and risks
What speaks for UNCY
- Renazorb Commercialization Upside
What speaks against UNCY
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| UNCY | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.3% |
| HUMA | n/a | 66.6x | n/a | -748.5% | -4840.8% | -76.3% |
| CNTN | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.6% |
| VYGR | n/a | 5.9x | n/a | -86.7% | -319.6% | -60.1% |
| IMUX | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -53.6% |
| DTIL | n/a | 2.3x | n/a | 97.0% | -98.7% | -57.9% |
| Peer median | n/a | 2.3x | n/a | 0.0% | -98.7% | -57.9% |
Frequently asked questions about Unicycive Therapeutics Inc (UNCY)
Is UNCY stock a good investment?
The cached TradeMates AI model rates Unicycive Therapeutics Inc as HOLD with an investment score of 62/100. Speculative buy based on strong technical recovery and extreme analyst upside ($22 target), despite pre-revenue status and high cash burn. This is algorithmic model output, not personal investment advice.
Is UNCY stock a buy?
The TradeMates model verdict for UNCY is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.